Publications

Publications

publication

Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617

View publication
publication

Targeted β- -Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study

View publication
publication

Initial Multicenter Experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results

View publication
publication

[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617

View publication
publication

Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry

View publication
publication

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

View publication
publication

161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer

View publication
publication

161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas

View publication
publication

First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study

View publication
publication

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

View publication
publication

161Terbium-Labeled Gold Nanoparticles as Nanoscale Brachytherapy Agents Against Breast Cancer

View publication
publication

The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE

View publication
publication

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

View publication